Search Results - Rizvi, N.A.

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

    16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) by Besse, B, Johnson, M, Janne, P.A, Garassino, M, Eberhardt, W.E.E, Peters, S, Toh, C.K, Kurata, T, Li, Z, Kowanetz, M, Mocci, S, Sandler, A, Rizvi, N.A

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes

    3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes by Schmid, P, Kowanetz, M, Koeppen, H, Zou, W, Wistuba, I, Kockx, M, Kadel, E.E, Chaft, J, Rizvi, N.A, Hirsch, F.R, Smith, D, Miley, N, Leveque, V, Shames, D.S, Sandler, A, Mellman, I, Chen, D.S, Hegde, P.S, Gettinger, S

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population

    127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-... by Garon, E.G, Rizvi, N.A, Leighl, N.B, Hui, R, Eder, J.P, Patnaik, A, Aggarwal, C, Horn, L, Balmanoukian, A.S, Gubens, M.A, Felip-Font, E, Costa, E. Carceny, Soria, J.C, Ahn, M.J, Arkenau, H.T, Lee, J.S, Robinet, G, Lubiniecki, G.M, Zhang, J, Emancipator, K, Rutledge, R, Dolled-Filhart, M, Gandhi, L

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

    191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first... by Peters, S., Antonia, S., Goldberg, S.B., Heymach, J.V., Kim, E.S., Nakagawa, K., Papadimitrakopoulou, V., Mukhopadhyay, P., McIntosh, S., Rizvi, N.A.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses

    137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling a... by Lena, H, Rizvi, N A, Wolf, J, Cappuzzo, F, Zalcman, G, Baas, P, Mazieres, J, Farsaci, B, Blackwood-Chirchir, M A, Ramalingam, S

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    97 POSTER Analysis of EGFR and KRAS mutations in circulating tumor DNA (cTDNA) from plasma of NSCLC patients in phase 2 trials of XL647

    97 POSTER Analysis of EGFR and KRAS mutations in circulating tumor DNA (cTDNA) from plasma of NSCLC patients in phase 2 trials of XL647 by Schimmoller, F, Rizvi, N.A, Vysotskaia, V.S, Funke, R.P, Dixon, S, Buller, R.E

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    137O Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses

    137O Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling a... by Lena, H., Rizvi, N.A., Wolf, J., Cappuzzo, F., Zalcman, G., Baas, P., Mazieres, J., Farsaci, B., Blackwood-Chirchir, M.A., Ramalingam, S.

    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Clinical usefulness of Doppler spectral analysis of graft dysfunction in living-related donor renal transplants

    Clinical usefulness of Doppler spectral analysis of graft dysfunction in living-related donor renal transplants by Khan, Z.A, Rana, T.A, Jamal, N.A, Hussain, A, Kazi, J, Naqvi, A, Rizvi, A

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: